We are live on ! Find out more
IDXG

Interpace Biosciences, Inc. Common Stock
IDXG

Delisted

IDXG was delisted on the 24th of February, 2021.

Back to rankings

26 hedge funds and large institutions have $34.7M invested in Interpace Biosciences, Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

0% more funds holding

Funds holding: 26 → 26 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

5% less capital invested

Capital invested by funds: $36.5M → $34.7M (-$1.74M)

Holders
26
Holders Change
–
Holders Change %
0%
% of All Funds
0.75%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
7
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$649K
2
HA
Heartland Advisors
Wisconsin
+$155K
3
MA
Minerva Advisors
Pennsylvania
+$52.5K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$50.9K
5
KCM
Kennedy Capital Management
Missouri
+$41.6K

Top Sellers

1
LCM
Leonard Capital Management
Florida
-$717K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$56.6K
3
PHS
Pekin Hardy Strauss
Illinois
-$32.7K
4
TRCT
Tower Research Capital (TRC)
New York
-$28.6K
5
Renaissance Technologies
Renaissance Technologies
New York
-$27K
Name Holding Trade Value Shares
Change 		Change in
Stake
BNP Paribas Financial Markets
26
BNP Paribas Financial Markets
France
$33 – – –
Manulife (Manufacturers Life Insurance)
27
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4 – – –
LCM
28
Leonard Capital Management
Florida
– -$717K -1,491 Closed
Deutsche Bank
29
Deutsche Bank
Germany
– -$26K -50 Closed
1
2

IDXG Hedge Fund Activity: Q1 2014 in Review

26 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q1 2014, worth a combined $34.7M — down 4.8% from $36.5M a quarter earlier.

Fund positioning in IDXG was balanced in Q1 2014: 2 funds opened new positions, 2 closed out, 7 added to existing stakes and 5 trimmed.

The largest buyer was Dimensional Fund Advisors, adding an estimated $649K. The largest seller was Leonard Capital Management, exiting entirely with an estimated $717K sold.

  • 26 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q1 2014, unchanged from Q4 2013.
  • Funds reported $34.7M of Interpace Biosciences, Inc. Common Stock stock for Q1 2014, down 4.8% quarter-over-quarter.
  • 2 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q1 2014 and 2 closed out, a net change of 0 holders.
  • The largest Interpace Biosciences, Inc. Common Stock buyer in Q1 2014 was Dimensional Fund Advisors, an estimated $649K added.
  • The largest Interpace Biosciences, Inc. Common Stock seller in Q1 2014 was Leonard Capital Management, an estimated $717K sold.

Based on aggregated 13F filings for Q1 2014.